Abstract
The use of plasma exchange (PE) in the treatment of systemic diseases has been progressively codified. In renal diseases, PE is clearly indicated in Goodpasture syndrome. In vasculitis, PE associated with antiviral drugs should be the first line treatment in polyarteritis nodosa associated with hepatitis B virus. In Wegener granulomatosis, PE should be used in case of renal failure. In the treatment of cryoglobulinemia, PE therapy should be combined with immunosuppressives drugs (type I) or alpha interferon (types II and III). During the course of lupus erythematosus, the indications of PE are restricted to immunosuppressive resistant forms, neurologic complications, association with a severe antiphospholipid syndrome, and thrombotic thrombopenic purpura with renal failure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
